ASTMANI DAVOLASHDAGI YANGI BIOLOGIK PREPARATLAR.
Keywords:
bronxial astma, biologik terapiya, monoklonal antikorlar, interleykinlar, og‘ir astma, IgE, dori samaradorligiAbstract
Bronxial astma bu surunkali yallig‘lanishli kasallik bo‘lib, bronxlar darajasida havoning cheklanishi, reversiv obstruktsiya va gipersezuvchanlik bilan kechadi. An’anaviy davo usullari, xususan inhalyatsion kortikosteroidlar va bronxolitiklar ko‘pchilik hollarda simptomlarni nazorat qilishda yordam beradi, biroq o‘rta va og‘ir darajadagi astma shakllarida ushbu vositalar yetarli klinik natijani bermaydi. So‘nggi yillarda immunologik mexanizmlarga asoslangan biologik preparatlar ishlab chiqildi va klinik amaliyotga joriy etildi. Ular interleykin-4, -5, -13 yoki IgE kabi maqsadli molekulalarni bloklab, yallig‘lanish jarayonini nazorat qilishda ancha samarali hisoblanadi. Ushbu maqolada biologik terapiyaga oid yangi dori vositalari, ularning ta’sir mexanizmlari va klinik samaradorligi ko‘rib chiqiladi.
References
1. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. 2024 Update.
2. Castro M. et al. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. New England Journal of Medicine. 2018; 378(26):2486–2496.
3. Bousquet J. et al. Anti-IgE therapy with omalizumab in allergic diseases: An update. Allergy. 2021; 76(7):1965–1976.
4. Pavord I.D. et al. Mepolizumab for Severe Eosinophilic Asthma: A 4-Year Open-Label Study. Lancet Respiratory Medicine. 2019; 7(10): 943–955.
5. FitzGerald J.M. et al. Benralizumab for patients with severe asthma. New England Journal of Medicine. 2016; 376(25):2448–2458.
6. Wechsler M.E. et al. Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma. New England Journal of Medicine. 2021; 384(19):1800–1809.
7. Pelaia C. et al. Biologics in severe asthma: the era of precision medicine. Pulmonary Pharmacology & Therapeutics. 2022; 73:102126.